Selected IIR references (for abstracts, see Lists of IIR Publications):
Bendtzen et al. Cytokine autoantibodies. In: Peter JB, Shoenfeld Y, eds. Autoantibodies. Amsterdam: Elsevier Science B.V., 1996:209-216. (Review).
Hansen MB. Human cytokine autoantibodies. Characteristics, test procedures and possible physiological and clinical significance. APMIS 1996; 104, Suppl. 59:1-33. (Thesis).
Svenson M, Herbrink P. Measurement of cytokine antibodies. Test development. Biotherapy 1997; 10:87-92.
Ross et al. Increased in vivo antibody activity against IL-1a, IL-6 and IFN-alpha following IVIg administration. Blood 1997; 90:2376-2380.
Bendtzen K. Autoantibodies to cytokines. Eur J Clin Invest 1998; 28: 300-1.
Bendtzen et al. High-avidity autoantibodies to cytokines. Immunol Today 1998; 19:209-11.
Svenson et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998; 91:2054-61.
Bendtzen et al. Detection of autoantibodies to cytokines. Mol Biotechnol 2000;14:251-61 (Review).
Bendtzen et al. Natural and induced anti-cytokine antibodies. In: Ciliberto G, Savino R, editors. Cytokine inhibitors. New York: Marcel Dekker; 2000. p. 53-95. (Review).
Ross et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706-712.
Bendtzen K. Anti-IFN BAb and NAb antibodies: A minireview. Neurology 2003;61, Suppl. 5:S6-S10.
Bendtzen K. Immunogenicitet af biologiske lægemidler. Erfaringer med betainterferon, EPO og anti-TNF [Immunogenicity of biopharmaceuticals. Experience with interferon-beta, EPO and anti-TNF](Review). Ugeskr Laeger 2003;48:4629-32.
Bendtzen K. Problemer ved klinisk brug af rekombinante proteiner [Problems with clinical use of recombinant proteins] (Editorial). Ugeskr Laeger 2003;48:4625.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N, Danish Multiple Sclerosis Study Group. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-91.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N. Antibodies to IFN-beta: the Danish National IFN-beta Project. Neurology 2003;61:S27-S28.
Gudbrandsdottir S, Larsen R, Sørensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Müller K. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22:118-24.
Gudbrandsdottir S, Bliddal H, Petri A, Terslev L, Danneskiold-Samsoe B, Bjørnhart B, Bendtzen K, Müller K. Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis. Scand J Rheumatol 2004;33:385-388.
Sorensen PS, Ross C, Bendtzen K, Koch-Henriksen N. Neutralising antibodies against interferon beta in multiple sclerosis. Lancet 2004;363:168-9 (letter).
Sørensen PS, Koch-Henriksen N, Pedersen CR, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Dansk Multipel Sklerose Gruppe. Betydningen af neutraliserende antistoffer mod interferon-beta hos patienter med attakvis multipel sklerose. Ugeskr Laeger 2004;166:3606-3609.
Bendtzen K. Natural and therapy-induced antibodies to cytokines. Drug Discovery Today 2004;9:259.
